Prelude Therapeutics (NASDAQ:PRLD) Rating Reiterated by HC W

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 376.19% from the stock’s previous close. Other equities […]

Related Keywords

, Renaissance Technologies , Boxer Capital , Blackrock Inc , Orbimed Advisors Llc , Morgan Stanley , Barclays , Securities Exchange Commission , Prelude Therapeutics Incorporated , Prelude Therapeutics , Get Free Report , Director Orbimed Advisors Llc , Exchange Commission , Street Corp , Therapeutics Incorporated , Prelude Therapeutics Daily , Nasdaq Prld , Sprld , Medical , Reiterated Rating , Hc Wainwright ,